EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease

References

• Mauch P.M. Controversies in the management of early stage Hodgkin's disease. Blood 1994; 83: 318–329
   PubMed Web of Science ®Google Scholar
• Urba W.J., Longo D.L. Hodgkin's disease. New England Journal of Medicine 1992; 326: 678–687
   PubMed Web of Science ®Google Scholar
• Hoppe R.T., Coleman C.N., Cox R.S., Rosenberg S.A., Kaplan H.S. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59: 455–465
   PubMed Web of Science ®Google Scholar
• Hellman S., Mauch P. Role of radiation therapy in the treatment of Hodgkin's disease. Cancer Treatment Reports 1982; 66: 915–923
   PubMedGoogle Scholar
• Koziner B., Myers J., Cirrincione C., Redman J., Cunningham I., Caravelli J., Nisce L.Z., McCormick B., Straus D.J., Mertelsmann R. Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities. American Journal of Medicine 1986; 80: 1067–1078
   PubMed Web of Science ®Google Scholar
• Carde P., Hagenbeek A., Hayat M., Monconduit M., Thomas J., Burgers M.J., Noordijk E.M., Tanguy A., Meerwaldt J.H., Le Fur R., Somers R., Kluin-Nelemans H.C., Busson A., Breed W.P., Bron D., Holdrinet A., Rutten E. H. J. M., Michiels J.J., Regnier R., Debusscher L., Musella R., Fargeot P., Thyss A., Cattan A., Rigal-Huguet F., Roth S., Caillou B., Dupouy N., Henry-Amar M. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology 1993; 11: 2258–2272
   PubMed Web of Science ®Google Scholar
• Noordijk E.M., Carde P., Mandard A.M., Mellink W.A., Monconduit M., Eghbali H., Tirelli U., Thomas J., Somers R., Dupouy N., Henry-Amar M. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Annals of Oncology 1994; 5(Suppl 2)107–112
   PubMedGoogle Scholar
• Gobbi P.G., Pieresca C., Frassoldati A., Carotenuto M., DiRenzo N., La Sala A., Berte R., Avanzini P., Federico M., Silingardi V., Ascari E. Vinblastine, Bleomycin and Methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: The Gruppo Italiano per lo Studio dei Linfomi experience. Journal of Clinical Oncology 1996; 14: 527–533
   PubMed Web of Science ®Google Scholar
• Longo D.L. Chemotherapy alone in the treatment of patients with early stage Hodgkin's disease. Annals of Oncology 1996; 7(Suppl 4)85–89
   PubMedGoogle Scholar
• Kinzie J.J., Hanks G.E., MacLean C.J., Kramer S. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals. Cancer 1983; 52: 2223–2226
   PubMed Web of Science ®Google Scholar
• Cornbleet M.A., Vitolo U., Ultmann J.E., Golomb H.M., Oleske D., Griem M.L., Ferguson D.J., Miller J.B. Pathologic stages IA and IIA Hodgkin's disease: results of treatment with radiotherapy alone (1968–1980). Journal of Clinical Oncology 1985; 3: 758–768
   PubMed Web of Science ®Google Scholar
• Meeker W.R., Richardson J.D., West W.O., Parker J.C. Critical evaluation of laparotomy and splenectomy in Hodgkin's disease. Archives of Surgery 1972; 105: 222–229
   PubMed Web of Science ®Google Scholar
• Longo D.L., Glatstein E., Duffey P.L., Young R.C., Hubbard S.M., Urba W.J., Wesley M.N., Raubitschek A., Jaffe E.S., Wiernik P.H., DeVita T. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial. Journal of Clinical Oncology 1991; 9: 906–917
   PubMed Web of Science ®Google Scholar
• Carde P., Burgers J.M., Henry-Amar M., Hayat M., Sizoo W., Van der Schueren E., Monconduit M., Noordijk E.M., Lustman-Marechal J., Tanguy A., de Pauw B., Cosset J.M., Cattan A., Schneider M., Thomas J., Meerwaldt J.H., Somers R., Tubiana M. Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. Journal of Clinical Oncology 1988; 6: 239–252
   PubMed Web of Science ®Google Scholar
• Anderson H., Crowther D., Deakin D.P., Ryder W.D., Radford J.A. A randomized study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. Annals of Oncology 1991; 2(Suppl.2)49–54
   PubMedGoogle Scholar
• Specht L., Gray R.G., Clarke M.J., Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3, 888 patients. Journal of Clinical Oncology 1998; 16: 830–843
   PubMed Web of Science ®Google Scholar
• Lund M.B., Kongerud J., Nome O., Abrahamsen A.F., Bjortuft O., Forfang K., Boe J. Lung function impairment in long-term survivors of Hodgkin's disease. Annals of Oncology 1995; 6: 495–501
   PubMed Web of Science ®Google Scholar
• Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. Journal of American Medical Association 1993; 270: 1949–1955
   PubMed Web of Science ®Google Scholar
• van Leeuwen F.E., Klokman W.J., Hagenbeek A., Noyon R., van den Belt-Dusebout A.W., van Kerkhoff E.H., van Heerde P., Somers R. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. Journal of Clinical Oncology 1994; 12: 312–325
   PubMed Web of Science ®Google Scholar
• Tucker M.A., Coleman C.N., Cox R.S., Varghese A., Rosenberg S.A. Risk of second cancers after treatment for Hodgkin's disease. New England Journal of Medicine 1988; 318: 76–81
   PubMed Web of Science ®Google Scholar
• Mauch P.M., Kalish L.A., Marcus K.C., Coleman C.N., Shulman L.N., Krill E., Come S., Silver B., Canellos G.P., Tarbell N.J. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 1996; 87: 3625–3632
   PubMed Web of Science ®Google Scholar
• Henry-Amar M., on behalf of the International Database on Hodgkin's Disease (IDHD). Second cancer after the treatment for Hodgkin's disease: A report from the Interntional Database on Hodgkin's disease. Annals of Oncology 1992; 3(Suppl.4)S117–S128
   Google Scholar
• Vassilakopoulos Th.P., Angelopoulou M.K., Grigorakis V., Boussiotis V.A., Kittas Ch., Papavassiliou K., Fessas Ph., Pangalis G.A. Clinical features of 455 patients with Hodgkin's disease: A 15-year experience of a single Haematology Unit. Third International Symposium on Hodgkin's Lymphoma. 1995, Koln (Abstr #104)
   Google Scholar
• Swerdlow A.J., Douglas A.J., Vaughan Hudson G., Vaughan Hudson B., Bennett M.H., Mac Lennan K.A. Risk of second primary cancers after Hodgkin's disease by type of treatment: Analysis of 2846 patients in the Bristish National Lymphoma Investigation. British Medical Journal 1992; 304: 1137–1143
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadonna G., Valagussa P., Zucali R., Viviani S., Villani F., Pagnoni A.M., Bonfante V., Musumeci R., Crippa F., Tesoro Tess J.D., Banfi A. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. Journal of Clinical Oncology 1987; 5: 27–37
   PubMed Web of Science ®Google Scholar
• Valagussa P., Santoro A., Fossati-Bellani F., Franchi F., Banfi A., Bonadonna G. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood 1982; 59: 488–494
   PubMed Web of Science ®Google Scholar
• Canellos G.P., Anderson J.R., Propert K.J., Nissen N., Cooper M.R., Henderson E.S., Green M.R., Gottlieb A., Peterson B.A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Horning S.J., Hoppe R.T, Mason J., Brown B.W., Hancock S.L., Baer D., Rosenberg S.A. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation vs vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. Journal of Clinical Oncology 1997; 15: 1736–1744
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos Th.P., Angelopoulou M.K., Kontopidou F.N., Siakantaris M.P., Barbounis A., Hadjioannou M., Boussiotis V.A., Kittas Ch., Pangalis G.A. Pure infradiaphragmatic Hodgkin's disease. Analysis of twenty five cases and review of the literature. Haema 1999; 2: 90–100
   Google Scholar
• Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Mauch P., Goodman R., Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978; 42: 1039–1045
   PubMed Web of Science ®Google Scholar
• Ifrah N., Hunault M., Jais J.P., Moreau P., Desablens B., Casassus P., Briere J., Le Maignan C., Andrieu J.M. Infradiaphragmatic Hodgkin's disease: Long term results of combined modality therapy. Leukemia and Lymphoma 1996; 21: 79–84
   PubMed Web of Science ®Google Scholar
• Canellos G.P., Petroni G.R., Barcos M., Duggan D.B., Peterson B.A. Etoposide, Vinblastine, and Doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Journal of Clinical Oncology 1995; 13: 2005–2011
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–259
   PubMed Web of Science ®Google Scholar
• Homing S.J., Rosenberg S.A., Hoppe R.T. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Annals of Oncology 1996; 7(Suppl 4)105–108
   PubMedGoogle Scholar
• Kaplan E., Meier P. ): Nonparapetric estimation from incomplete observations. Journal of American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Bonadonna G., Gianni L., Santoro A., Bonfante V., Bidoli P., Casali P., Demicheli R., Valagussa P. Drugs ten years later: Epirubicin. Annals of Oncology 1993; 4: 359–369
   PubMed Web of Science ®Google Scholar
• Andrieu J.M., Montagnon B., Asselain B., Bayle-Weisgerber C., Chastang C., Teillet F., Bernard J. Chemotherapy-radiotherapy association in Hodgkin's disease, clinical stages IA, II2A: Results of a prospective clinical trial with 166 patients. Cancer 1980; 46: 2126–2130
   PubMed Web of Science ®Google Scholar
• Zittoun R., Audebert A., Hoerni B., Bernadou A., Krulik M., Rojouan J., Eghbali H., Merle-Beral H., Parlier Y., Diebold J., Grellet J., Laugier A., Debray J. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. Journal of Clinical Oncology 1985; 3: 207–214
   PubMed Web of Science ®Google Scholar
• Colonna P., Jais J.P., Desablens B., Harousseau J.L., Briere J., Boasson M., Lemevel A., Casassus P., Le Prise P.Y., Guilhot F., Ghandour C., Lejeune F., Andrieu J.M. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. Journal of Clinical Oncology 1996; 14: 1928–1935
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonfante V., Viviani S., Devizzi L., Zanini M., Soncini F., Gasparini M., Valagussa P., Bonadonna G. Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (HD). Proceedings of the American Society of Clinical Oncology 1996; 15: 415
   Google Scholar
• Horning S.J., Hoppe R.T., Hancock S.L., Rosenberg S.A. Vinblastine, Bleomycin and Methotrexate: An effective adjuvant in favorable Hodgkin's disease. Journal of Clinical Oncology 1988; 6: 1822–1831
   PubMed Web of Science ®Google Scholar
• Bates N.P., Williams M.V., Bessell E.M., Vaughan Hudson G., Vaughan Hudson B. Efficacy and toxicity of Vinblastine, Bleomycin and Methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. Journal of Clinical Oncology 1994; 12: 288–296
   PubMed Web of Science ®Google Scholar
• Carde P., Noordijk E.M., Hagenbeek A., Thomas J., Tirelli U., Moncondult M., Eghbali H., Burgers J.M.V., Tanguy A., Gerrits W.B.J., Vovk M., Verschueren T., Keuning J.J., de Bock R., Cosset J.M., Mellink W.A.M., Kluin-Nelemans J.C., Monfardini S., Vanuytsel L., Mandard A.M., Dupouy N., Henry-Amar M. EBVP chemotherapy plus irradiation provides Event-Free Survival (EFS) superior to subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin's disease, but inferior to MOPP-ABV plus irradiation in unfavorable cases: The EORTC-GPMC H7 randomized trials. Leukemia and Lymphoma 1998; 29(Suppl 1), (abstr O6)
   Google Scholar
• Hagemeister F.B., Fuller L., McLaughlin P., Rodriguez M., Romaguera J., Swan F., Cabanillas F. NOVP and radiotherapy for early-staged Hodgkin's disease: An interim analysis. Annals of Oncology 1992; 3(Suppl 4)87–90
   PubMedGoogle Scholar
• Sears J.D., Greven K.M., Ferree C.R., Agostino R.B. Definitive irradiation in the treatment of Hodgkin's disease: Analysis of outcome, prognostic factors, and long term complications. Cancer 1997; 79: 145–151
   PubMed Web of Science ®Google Scholar
• Doria R., Holford T., Farber L.R., Prosnitz L.R., Cooper D.L. Second solid malignancies after combined modality therapy for Hodgkin's disease. Journal of Clinical Oncology 1995; 13: 2016–2022
   PubMed Web of Science ®Google Scholar
• Ekert H., Waters K.D., Smith P.J., Toogood I., Mauger D. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. Journal of Clinical Oncology 1988; 6: 1845–1850
   PubMed Web of Science ®Google Scholar
• Brizel D.M., Winer E.P., Prosnitz L.R., Scott J., Crawford J., Moore J.O., Gockerman J.P. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. International Journal of Radiation Oncology Biology, Physics 1990; 19: 535–542
   PubMed Web of Science ®Google Scholar
• Diehl V., Loeffler M., Pfreundschuh M., Ruehl U., Hasenclever D., Nisters-Backes H., Sieber M., Smith K., Tesch H., Geilen W., Adler M., Bartels H., Brandenburg U., Diezler P., Doelken G., Enzian J., Fuchs R., Gassmann W., Gerhartz H., Hagenaukamp U., Hecht T., Hiller E., Hinkelbein H., Lathan B., Kirchner H., Kuehn G., Kuerten H., Loos U., Makoski B., Oertel W., Petsch S., Pfab R., Pflueger H., Planker M., Rohloff R., Sack H., Samandari S., Sauer R., Schalk K., Schmitz G., Schoppe W., Schwieder G., Szepesi S., Teichmann J., Wilhelmy W., Worst P., Fischer R., Georgii A., Huebner K., Schwarze E.-W. Further chemotherapy versus low dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Annals of Oncology 1995; 6: 901–910
   PubMed Web of Science ®Google Scholar
• Fabian C.J., Mansfield C.M., Dahlberg S., Jones S.E., Miller T.P., van Slyck E., Grozea P.N., Morrison F.S., Coltman C.A., Fisher R.I. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. A Southwest Oncology Group randomized study. Annals of Internal Medicine 1993; 120: 903–912
   Web of Science ®Google Scholar
• Loeffler M., Diehl V., Pfreundschuh M., Ruhl U., Hasenclever D., Nisters-Backes H., Sieber M., Tesch H., Franklin J., Geilen W., Bartels H., Cartoni C., Dolken G., Enzian J., Fuchs R., Gaßmann W., Gerhartz H., Hagen-Aukamp U, Hiller E., Hinkelbein H., Hinterberger W., Kirchner H., Koch P., Kruger B., Kurten H., Kutzner K., Loos U., Mende W., Muller H., Oertel W., Petsch S., Pfab R., Pfluger H., Rohloff R., Sauer R., Schalk K., Schick H.D., Schoppe W., Szepesi S., Teichmann J., Worst P., Fischer R., Georgii A., Hubner K., Schwarze E.W. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. Journal of Clinical Oncology 1997; 15: 2275–2287
   PubMed Web of Science ®Google Scholar
• Wolf J., Tesch H., Parsa-Parsi R., Engert A., Diehl V. Current clinical trials for the treatment of adult Hodgkin's disease: Common strategies and perspectives. Annals of Oncology 1998; 9(Suppl 5)S79–S82
   PubMedGoogle Scholar
• Lund M.B., Ihlen H., Voss B.M., Abrahamsen A.F., Nome O., Kongerud J., Stugaard M., Forfang K. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: An echocardiographic study. Heart 1996; 75: 591–595
   PubMed Web of Science ®Google Scholar
• Hancock S.L., Tucker M.A., Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. Journal of National Cancer Institute 1993; 85: 25–31
   PubMed Web of Science ®Google Scholar
• Connors J.M., Reece D.E., Diehl V., Engert A. Hodgkin's lymphoma: New approaches to treatment. Hematology 1998, American Society of Hematology, Education Program Book. 1998; 274–295
   Google Scholar
• Pavlovsky S., Maschio M., Santarelli M.T., Muriel F.S., Corrado C., Garcia I., Schwartz L., Montero C., Sanahuja F.L., Magnasco O., Rana R., Cavagnaro F. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. Journal of National Cancer Institute 1988; 80: 1466–1473
   PubMed Web of Science ®Google Scholar
• Rueda A., Alba E., Ribelles N., Sevilla I., Ruiz I., Miramon J. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: A pilot study. Journal of Clinical Oncology 1997; 15: 1118–1122
   PubMed Web of Science ®Google Scholar